January 2017

New Product - Afluria Quad

Afluria Quad (inactivated quadrivalent influenza vaccine) is a purified, inactivated, split virion (split virus) vaccine containing antigens for the 2017 influenza season representative of the following types: A/Singapore/GP1908/2015 (IVR-180) (A/Michigan/45/2015 (H1N1) – like): 15 μg haemagglutinin per dose; A/Hong Kong/4801/2014 (NYMC X-263B) (A/Hong Kong/4801/2014 (H3N2) – like): 15 μg haemagglutinin per dose; B/Phuket/3073/2013 (B/Phuket/3073/2013- like): 15 μg haemagglutinin per dose; B/Brisbane/46/2015 (B/Brisbane/60/2008 - like): 15 μg haemagglutinin per dose. Seroprotection is generally obtained within 2 to 3 weeks. The duration of post-vaccination immunity to homologous strains, or to strains closely related to the vaccine strains, varies but is usually 6 to 12 months. Afluria quad is indicated for the prevention of influenza caused by Influenza Virus, Types A and B contained in the vaccine. The vaccine is indicated for use only in persons aged 18 years and over. Afluria Quad vaccine is contraindicated in children < 18 years because the safety and efficacy in this age group has not been established. Afluria Quad vaccine is contraindicated in individuals with history of hypersensitivity to egg protein or any of the constituents or trace residues of this vaccine. Immunization should generally be postponed in individuals having a febrile illness or acute infection. Afluria Quad is available as a 0.5 mL suspension for injection with fixed-needle in packs of 1’s and 10’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629